Merck Patent Gmbh

Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Merck Patent Gesellschaft MIT Beschrankter Haftung

Matthias Grell

Hans-Peter Buchstaller

Frank Zenke

Christian Sirrenberg

Christiane Amendt

Matthias Wiesner

Oliver Schadt

Lars Thore Burgdorf

Dieter Dorsch

Manfred Baumgarth

Dirk Finsinger

Klaus Pfizenmaier

Herwig Brunner

Thomas Schiestel

David Bruge

Klaus Dücker

Peter Scheurich

Claus Fittschen

Günter Tovar

Angela Hammer

Tom Mikkelsen

Martin Andreas Picard

Roger Stupp

Johannes Nippgen

Michael Weller

Ulrike Grimm

Andreas Harstrick

Michael Prof Weller

The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Methylene urea derivatives

Compounds of the formula I in which X, Y, R, R, R, Rhave the meanings indicated in Claim, are inhibitors of cell proliferation and can be employed for the treatment of tumors. 

Hydroxyquinoline derivatives

The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients. 

Benzimidazole carboxamides as raf kinase inhibitors

The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.

Benzimidazole derivatives as raf kinase inhibitors

Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours 

Pyrrole derivatives

The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Glycinamide derivatives as raf-kinase inhibitors

The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.

Nanoparticles comprising biologically active TNF which is immobilized on the same

Lipid Binding Protein 4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Lipid Binding Protein 4 polypeptides and polynucleotides in diagnostic assays.

Lipid binding protein 4

Growing community of inventors

Darmstadt, Germany

Matthias Grell